SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: GlobeNewswire
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether ADC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 9, 2022, Morgan Stanley downgraded the Company’s stock to Equal Weight from Overweight, citing market penetration concerns regarding the Company’s Zynlonta product. On this news, ADC’s stock price fell $0.35 per share, or 5.37%, to close at $6.17 per share on September 9, 2022. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founde
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics SA (NYSE: ADCT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
- ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- ADC Therapeutics SA (NYSE: ADCT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.MarketBeat
- US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ADCT
Earnings
- 3/13/24 - Miss
ADCT
Sec Filings
- 3/15/24 - Form 424B3
- 3/15/24 - Form 424B3
- 3/15/24 - Form EFFECT
- ADCT's page on the SEC website